These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

194 related articles for article (PubMed ID: 9541691)

  • 1. Oxaliplatin as single agent in previously untreated colorectal carcinoma patients: a phase II multicentric study.
    Díaz-Rubio E; Sastre J; Zaniboni A; Labianca R; Cortés-Funes H; de Braud F; Boni C; Benavides M; Dallavalle G; Homerin M
    Ann Oncol; 1998 Jan; 9(1):105-8. PubMed ID: 9541691
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase II trial of oxaliplatin as first-line chemotherapy in metastatic colorectal cancer patients. Digestive Group of French Federation of Cancer Centers.
    Bécouarn Y; Ychou M; Ducreux M; Borel C; Bertheault-Cvitkovic F; Seitz JF; Nasca S; Nguyen TD; Paillot B; Raoul JL; Duffour J; Fandi A; Dupont-André G; Rougier P
    J Clin Oncol; 1998 Aug; 16(8):2739-44. PubMed ID: 9704726
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Second-line chemotherapy with weekly oxaliplatin and high-dose 5-fluorouracil with folinic acid in metastatic colorectal carcinoma: a Hellenic Cooperative Oncology Group (HeCOG) phase II feasibility study.
    Janinis J; Papakostas P; Samelis G; Skarlos D; Papagianopoulos P; Fountzilas G
    Ann Oncol; 2000 Feb; 11(2):163-7. PubMed ID: 10761750
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Two consecutive phase II studies of oxaliplatin (L-OHP) for treatment of patients with advanced colorectal carcinoma who were resistant to previous treatment with fluoropyrimidines.
    Machover D; Diaz-Rubio E; de Gramont A; Schilf A; Gastiaburu JJ; Brienza S; Itzhaki M; Metzger G; N'Daw D; Vignoud J; Abad A; Francois E; Gamelin E; Marty M; Sastre J; Seitz JF; Ychou M
    Ann Oncol; 1996 Jan; 7(1):95-8. PubMed ID: 9081400
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Oxaliplatin plus raltitrexed in patients with advanced colorectal carcinoma: results of a Phase I-II trial.
    Scheithauer W; Kornek GV; Ulrich-Pur H; Penz M; Raderer M; Salek T; Haider K; Kwasny W; Depisch D
    Cancer; 2001 Apr; 91(7):1264-71. PubMed ID: 11283925
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intermittent weekly high-dose capecitabine in combination with oxaliplatin: a phase I/II study in first-line treatment of patients with advanced colorectal cancer.
    Scheithauer W; Kornek GV; Raderer M; Schüll B; Schmid K; Längle F; Huber H
    Ann Oncol; 2002 Oct; 13(10):1583-9. PubMed ID: 12377646
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Oxaliplatin with weekly bolus fluorouracil and low-dose leucovorin as first-line therapy for patients with colorectal cancer.
    Hochster H; Chachoua A; Speyer J; Escalon J; Zeleniuch-Jacquotte A; Muggia F
    J Clin Oncol; 2003 Jul; 21(14):2703-7. PubMed ID: 12860947
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study.
    Suenaga M; Mizunuma N; Matsusaka S; Shinozaki E; Ozaka M; Ogura M; Yamaguchi T
    Drug Des Devel Ther; 2015; 9():3099-108. PubMed ID: 26124634
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Capecitabine and oxaliplatin in advanced colorectal cancer: a dose-finding study.
    Zeuli M; Di Costanzo E; Sdrobolini A; Gasperoni S; Paoloni FP; Carpi A; Moscetti L; Cherubini R; Cognetti F; ;
    Ann Oncol; 2001 Dec; 12(12):1737-41. PubMed ID: 11843252
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Evaluation of oxaliplatin dose intensity in bimonthly leucovorin and 48-hour 5-fluorouracil continuous infusion regimens (FOLFOX) in pretreated metastatic colorectal cancer. Oncology Multidisciplinary Research Group (GERCOR).
    Maindrault-Goebel F; de Gramont A; Louvet C; André T; Carola E; Gilles V; Lotz JP; Tournigand C; Mabro M; Molitor JL; Artru P; Izrael V; Krulik M
    Ann Oncol; 2000 Nov; 11(11):1477-83. PubMed ID: 11142489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Chronomodulated administration of oxaliplatin plus capecitabine (XELOX) as first line chemotherapy in advanced colorectal cancer patients: phase II study.
    Santini D; Vincenzi B; Schiavon G; Di Seri M; Virzí V; Spalletta B; Caricato M; Coppola R; Tonini G
    Cancer Chemother Pharmacol; 2007 Apr; 59(5):613-20. PubMed ID: 16944151
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Bimonthly high-dose leucovorin, 5-fluorouracil infusion and oxaliplatin (FOLFOX3) for metastatic colorectal cancer resistant to the same leucovorin and 5-fluorouracil regimen.
    André T; Louvet C; Raymond E; Tournigand C; de Gramont A
    Ann Oncol; 1998 Nov; 9(11):1251-3. PubMed ID: 9862058
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oxaliplatin: a review of its use in the management of metastatic colorectal cancer.
    Wiseman LR; Adkins JC; Plosker GL; Goa KL
    Drugs Aging; 1999 Jun; 14(6):459-75. PubMed ID: 10408744
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Multicenter phase II study of bimonthly high-dose leucovorin, fluorouracil infusion, and oxaliplatin for metastatic colorectal cancer resistant to the same leucovorin and fluorouracil regimen.
    André T; Bensmaine MA; Louvet C; François E; Lucas V; Desseigne F; Beerblock K; Bouché O; Carola E; Merrouche Y; Morvan F; Dupont-André G; de Gramont A
    J Clin Oncol; 1999 Nov; 17(11):3560-8. PubMed ID: 10550155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. High antitumor effectiveness against metastatic colorectal cancer.
    Lévi F; Misset JL; Brienza S; Adam R; Metzger G; Itzakhi M; Caussanel JP; Kunstlinger F; Lecouturier S; Descorps-Declère A
    Cancer; 1992 Feb; 69(4):893-900. PubMed ID: 1735081
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Raltitrexed plus oxaliplatin as first-line chemotherapy in metastatic colorectal carcinoma: a multicentric phase II trial.
    Neri B; Doni L; Fulignati C; Perfetto F; Turrini M; Andreoli F; Pantalone D; Pernice LM; Taruffi F; Martini V; Poma A; Valeri A; Bacci G; Sancez L; Moretti R
    Anticancer Drugs; 2002 Aug; 13(7):719-24. PubMed ID: 12187328
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Activity and safety of oxaliplatin with weekly 5-fluorouracil bolus and low-dose leucovorin as first-line treatment for advanced colorectal cancer.
    Cassinello J; Escudero P; Salud A; Marcos F; Pujol E; Pérez-Carrión R; Colmenarejo A; González del Val R; Valero J; Oruezábal MJ; Guillem V; García I; Arcediano A; Marfà X
    Clin Colorectal Cancer; 2003 Aug; 3(2):108-12. PubMed ID: 12952567
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Oxaliplatin: a review of preclinical and clinical studies.
    Raymond E; Chaney SG; Taamma A; Cvitkovic E
    Ann Oncol; 1998 Oct; 9(10):1053-71. PubMed ID: 9834817
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Oxaliplatin. A review of its pharmacological properties and clinical efficacy in metastatic colorectal cancer and its potential in other malignancies.
    Culy CR; Clemett D; Wiseman LR
    Drugs; 2000 Oct; 60(4):895-924. PubMed ID: 11085200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase II trial of modified FOLFOX as first-line chemotherapy in advanced colorectal cancer.
    Xiong JP; Zhang L; Zhong LX; Qiu F; Xu J; Tao QS; Xiang XJ; Yu F; Tang XM
    Anticancer Drugs; 2007 Oct; 18(9):1103-7. PubMed ID: 17704661
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.